Literature DB >> 10484767

Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.

O Geneste1, C Bidaud, G De Vita, R M Hofstra, S Tartare-Deckert, C H Buys, G M Lenoir, M Santoro, M Billaud.   

Abstract

The RET gene codes for a transmembrane tyrosine kinase which is a subunit of a multimeric complex that acts as a receptor for four structurally related molecules: the glial cell line-derived neurotrophic factor (GDNF), neurturin, artemin and persephin. Germline mutations of RET cause a dominantly inherited dysgenesis of the enteric nervous system known as Hirschsprung's disease (HSCR; aganglionosis megacolon). The majority of HSCR mutations results either in a reduction of dosage of the RET protein or in the loss of RET function. Two novel distinct mutations of RET that led either to the deletion of codon 1059 (denoted Delta1059) or to the substitution of a Pro for Leu1061 have been identified in five HSCR families. In one large pedigree, two children born from asymptomatic consanguineous parents presented a severe form of HSCR and were found to carry the mutation at codon 1061 in the homozygous state. A tyrosine residue at position 1062 is an intracytoplasmic docking site that enables RET to recruit several signalling molecules, including the Shc adaptor protein. We now report that both HSCR mutations impair the fixation of Shc to RET and consequently prevent its phosphorylation. In addition, quantitative analysis in PC12 cells reveals that mutation Delta1059 inactivates the ability of RET to transduce a downstream signal whereas mutation L1061P only partially inhibits the signalling of RET. Finally, we provide evidence that these effects are partly mediated via the disruption of the RET/Shc interaction. Collectively, these results demonstrate that HSCR can be ascribed to mutations of RET which interfere with the binding of transduction effectors, such as Shc, and further provide a biochemical explanation for the phenotype of patients carrying a homozygous mutation at codon 1061. Finally, these data indicate that Y1062 is a multifunctional docking site that confers to RET the capacity to engage downstream signalling pathways which exert a crucial role during enteric neurogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484767     DOI: 10.1093/hmg/8.11.1989

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  Genetic basis of Hirschsprung's disease.

Authors:  Paul K H Tam; Mercè Garcia-Barceló
Journal:  Pediatr Surg Int       Date:  2009-06-12       Impact factor: 1.827

Review 2.  Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

Authors:  S W Moore; M G Zaahl
Journal:  Pediatr Surg Int       Date:  2008-03-26       Impact factor: 1.827

Review 3.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

4.  RET and EDNRB mutation screening in patients with Hirschsprung disease: Functional studies and its implications for genetic counseling.

Authors:  Titis Widowati; Shamiram Melhem; Suryono Y Patria; Bianca M de Graaf; Richard J Sinke; Martijn Viel; Jos Dijkhuis; Ahmad H Sadewa; Rochadi Purwohardjono; Yati Soenarto; Robert Mw Hofstra; Yunia Sribudiani
Journal:  Eur J Hum Genet       Date:  2015-09-23       Impact factor: 4.246

5.  Low RET mutation frequency and polymorphism analysis of the RET and EDNRB genes in patients with Hirschsprung disease in Taiwan.

Authors:  Trang-Tiau Wu; Tsui-Wei Tsai; Chao-Ta Chu; Zen-Fung Lee; Chuan-Mao Hung; Ching-Chyuan Su; Shuan-Yow Li; Mingli Hsieh; Chuan Li
Journal:  J Hum Genet       Date:  2005-04-15       Impact factor: 3.172

6.  Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Authors:  R M Melillo; M Santoro; S H Ong; M Billaud; A Fusco; Y R Hadari; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis.

Authors:  B Mograbi; R Bocciardi; I Bourget; T Juhel; D Farahi-Far; G Romeo; I Ceccherini; B Rossi
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

8.  The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Giuliana Pelicci; Flavia Troglio; Alessandra Bodini; Rosa Marina Melillo; Valentina Pettirossi; Laura Coda; Antonio De Giuseppe; Massimo Santoro; Pier Giuseppe Pelicci
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 9.  Structure and physiology of the RET receptor tyrosine kinase.

Authors:  Carlos F Ibáñez
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

10.  A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia.

Authors:  Mayumi Jijiwa; Toshifumi Fukuda; Kumi Kawai; Akari Nakamura; Kei Kurokawa; Yoshiki Murakumo; Masatoshi Ichihara; Masahide Takahashi
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.